Li Z D, Lu T
Department of Head and Neck Surgery, Liaoning Tumour Hospital, Shenyang 110042, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Dec 7;53(12):918-924. doi: 10.3760/cma.j.issn.1673-0860.2018.12.009.
To evaluate the efficacies of different treatment modalities for patients with advanced hypopharyngeal cancers, which were treated by induction chemotherapy and surgery combined with radiotherapy or concurrent chemoradiotherapy. A retrospective analysis was performed on the complete clinical and follow-up data of 92 patients with pathologically confirmed hypopharyngeal squamous cell carcinoma treated at Liaoning Tumor Hospital from January 2011 to December 2016. The tumor clinical staging was as follows: stage Ⅱ in 3 cases, stage Ⅲ in 33 cases, and stage Ⅳ in 56 cases. All patients underwent electronic esophagoscopy before treatment to remove esophageal cancer patients. The patients and their families chose voluntarily their desirable treatments from following modalities: A. Induction chemotherapy sensitivity plus radiotherapy or concurrent chemoradiotherapy, otherwise induction chemotherapy insensitivity plus surgical treatment; B. Surgical treatment plus radiotherapy or concurrent chemoradiotherapy, with drugs to control adverse reactions. The Kaplan-Meier method was used to calculate OS rates and Log-rank test was used to compare the OS rates between the two groups. Crosstabs was used to compare the difference in the 1, 3 and 5-year OS rates and the organ preservation rates between group A and group B, using chi-square test as non-parametric test. Fifty-two patients were enrolled in group A, after 2 cycles of induction chemotherapies with TPF(docetaxel, cisplatine, 5-Fu), there were 46 sensitive cases with primary lesions reduced by ≥50% (including 5 cases with tumor complete response) and 6 insensitive cases with primary lesions reduced by <50%. The 46 sensitive patients were treated with radiotherapy or concurrent chemoradiotherapy according to their physical conditions and 6 insensitive patients treated with surgery, including total laryngectomy for 5 cases and partial laryngectomy for one case. The 1, 3, and 5-year OS for 52 patients in group A were 91.93%, 49.59%, and 37.20%, respectively, with an organ preservation rate of 90.4% (47/52). Forty patients were enrolled in group B, including 33 cases with total laryngectomy and 7 cases with partial laryngectomy. The 1, 3, and 5-year OS for 40 patients in group B were 77.50%, 57.86% and 43.41%, respectively, with an organ preservation rate of 17.5%(7/40). The 1-year OS of group A was higher than group B (χ(2)=4.349, <0.05), and there was no statistical difference in the 3-year or 5-year OS between two groups. The organ preservation rate of 90.4% (47/52) in group A was higher than that (17.5%, 17/40) in group B, with a significant difference (χ(2)=49.539, <0.001). The clinical effectiveness for advanced hypopharyngeal carcinoma is still poor, and surgical treatment is still the main treatment method. According to the results of induction chemotherapy, radiotherapy, concurrent chemoradiotherapy or surgical treatment can be chosen, and ideal and feasible treatment modalities may improve the quality of life of patients, with high OS rate laryngeal preservation rate.
为评估不同治疗方式对晚期下咽癌患者的疗效,这些患者接受了诱导化疗以及手术联合放疗或同步放化疗。对2011年1月至2016年12月在辽宁省肿瘤医院接受治疗的92例经病理确诊的下咽鳞状细胞癌患者的完整临床和随访数据进行回顾性分析。肿瘤临床分期如下:Ⅱ期3例,Ⅲ期33例,Ⅳ期56例。所有患者在治疗前均接受电子食管镜检查以排除食管癌患者。患者及其家属从以下治疗方式中自愿选择他们期望的治疗方法:A.诱导化疗敏感加放疗或同步放化疗,否则诱导化疗不敏感加手术治疗;B.手术治疗加放疗或同步放化疗,并使用药物控制不良反应。采用Kaplan-Meier法计算总生存率(OS),并使用Log-rank检验比较两组的OS率。使用交叉表比较A组和B组1年、3年和5年OS率以及器官保留率的差异,使用卡方检验作为非参数检验。A组纳入52例患者,在接受2周期TPF(多西他赛、顺铂、5-氟尿嘧啶)诱导化疗后,有46例敏感病例,原发灶缩小≥50%(包括5例肿瘤完全缓解),6例不敏感病例,原发灶缩小<50%。46例敏感患者根据身体状况接受放疗或同步放化疗,6例不敏感患者接受手术治疗,其中5例行全喉切除术,1例行部分喉切除术。A组52例患者的1年、3年和5年OS分别为91.93%、49.59%和37.20%,器官保留率为90.4%(47/52)。B组纳入40例患者,其中33例行全喉切除术,7例行部分喉切除术。B组40例患者的1年、3年和5年OS分别为77.50%、57.86%和43.41%,器官保留率为17.5%(7/40)。A组的1年OS高于B组(χ(2)=4.349,P<0.05),两组3年或5年OS无统计学差异。A组90.4%(47/52)的器官保留率高于B组(17.5%,17/40),差异有统计学意义(χ(2)=49.539,P<0.001)。晚期下咽癌的临床疗效仍然较差,手术治疗仍然是主要治疗方法。根据诱导化疗结果,可选择放疗、同步放化疗或手术治疗,理想且可行的治疗方式可能提高患者生活质量,具有较高的OS率和喉保留率。